Lunac Therapeutics Limited (11317849) is a private limited with share capital incorporated on 18/04/2018 (8 years old) and registered in london, WC2N5NT. The company operates under SIC code 72190 - other research and experimental development on natural sciences and engineering.
Lunac therapeutics is a spin out from the university of leeds, uk and is pursuing the discovery of next generation oral anticoagulant therapies with a reduced risk of causing bleeding compared to current treatments. the business is founded on ip generated by professor helen philippou (professor of t...
Change Registered Office Address Company With Date Old Address New Address
Category:Address
Date:29-05-2026
Liquidation Voluntary Statement Of Affairs
Category:Insolvency
Date:29-05-2026
Liquidation Voluntary Appointment Of Liquidator
Category:Insolvency
Date:28-05-2026
Gazette Notice Compulsory
Category:Gazette
Date:28-04-2026
Termination Director Company With Name Termination Date
Category:Officers
Date:08-09-2025
Confirmation Statement With No Updates
Category:Confirmation Statement
Date:24-04-2025
Accounts With Accounts Type Small
Category:Accounts
Date:28-02-2025
Confirmation Statement With No Updates
Category:Confirmation Statement
Date:18-04-2024
Cessation Of A Person With Significant Control
Category:Persons With Significant Control
Date:12-03-2024
Accounts With Accounts Type Small
Category:Accounts
Date:29-02-2024
Termination Director Company With Name Termination Date
Category:Officers
Date:29-12-2023
Mortgage Create With Deed With Charge Number Charge Creation Date
Category:Mortgage
Date:08-11-2023
Confirmation Statement With No Updates
Category:Confirmation Statement
Date:14-06-2023
Accounts With Accounts Type Small
Category:Accounts
Date:14-12-2022
Appoint Person Director Company With Name Date
Category:Officers
Date:31-05-2022
Accounts With Accounts Type Small
Category:Accounts
Date:31-05-2022
Confirmation Statement With No Updates
Category:Confirmation Statement
Date:24-05-2022
Change Account Reference Date Company Previous Extended
Category:Accounts
Date:22-03-2022
Confirmation Statement With Updates
Category:Confirmation Statement
Date:19-05-2021
Resolution
Category:Resolution
Date:13-04-2021
Capital Allotment Shares
Category:Capital
Date:25-03-2021
Resolution
Category:Resolution
Date:10-03-2021
Change Registered Office Address Company With Date Old Address New Address
Category:Address
Date:05-02-2021
Change To A Person With Significant Control
Category:Persons With Significant Control
Date:03-02-2021
Accounts With Accounts Type Small
Category:Accounts
Date:09-10-2020
Notification Of A Person With Significant Control
Category:Persons With Significant Control
Date:18-05-2020
Capital Allotment Shares
Category:Capital
Date:07-05-2020
Notification Of A Person With Significant Control
Category:Persons With Significant Control
Date:01-05-2020
Withdrawal Of A Person With Significant Control Statement
Category:Persons With Significant Control
Date:01-05-2020
Appoint Person Director Company With Name Date
Category:Officers
Date:01-05-2020
Confirmation Statement With Updates
Category:Confirmation Statement
Date:30-04-2020
Accounts With Accounts Type Dormant
Category:Accounts
Date:21-12-2019
Termination Director Company With Name Termination Date
Category:Officers
Date:15-11-2019
Resolution
Category:Resolution
Date:27-10-2019
Capital Allotment Shares
Category:Capital
Date:23-10-2019
Appoint Person Director Company With Name Date
Category:Officers
Date:26-09-2019
Appoint Person Director Company With Name Date
Category:Officers
Date:26-09-2019
Appoint Person Director Company With Name Date
Category:Officers
Date:25-09-2019
Capital Allotment Shares
Category:Capital
Date:12-09-2019
Capital Alter Shares Subdivision
Category:Capital
Date:12-09-2019
Resolution
Category:Resolution
Date:12-09-2019
Confirmation Statement With No Updates
Category:Confirmation Statement
Date:24-04-2019
Incorporation Company
Category:Incorporation
Date:18-04-2018
Innovate Grants
2
This company received a grant of £1610864.5 for Development Of First-In Class Small Molecule Preclinical Candidate Anticoagulant Targeting Activated Factor Xii With Minimal Risk Of Bleeding. The project started on 01/09/2019 and ended on 31/05/2021.
This company received a grant of £249917.0 for Continuity Award Of Development Of First-In Class Small Molecule Preclinical Candidate Anticoagulant Targeting Activated Factor Xii With Minimal Risk Of Bleeding -105439. The project started on 01/06/2020 and ended on 30/11/2020.